ARVN Arvinas Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARVN

Price (delayed)

$9.01

Market cap

$589.13M

P/E Ratio

33.37

Dividend/share

N/A

EPS

$0.27

Enterprise value

$502.83M

?
Relative Growth: Rel. Growth: 83
Relative Strength: Rel. Strength: 29
Relative Valuation: Rel. Valuation: 65
Relative Profitability: Rel. Profitability: 59

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
The EPS has soared by 127% YoY and by 108% from the previous quarter
The company's net income has surged by 113% YoY and by 104% QoQ
The company's equity rose by 45% QoQ but it fell by 8% YoY
The gross profit has contracted by 17% YoY
Arvinas's revenue has decreased by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arvinas.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ARVN

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
1.58%
1 week
3.8%
1 month
11.23%
1 year
27.08%
YTD
-24.03%
QTD
8.42%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$316.7M
Gross profit
$307.7M
Operating income
-$18.1M
Net income
$9.3M
Gross margin
97.2%
Net margin
2.9%
The net margin has surged by 115% year-on-year and by 101% since the previous quarter
The company's net income has surged by 113% YoY and by 104% QoQ
Arvinas's operating margin has soared by 98% from the previous quarter and by 82% YoY
ARVN's operating income has soared by 93% from the previous quarter and by 85% YoY

Price vs fundamentals

How does ARVN's price correlate with its fundamentals

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
33.37
P/B
1.03
P/S
1.84
EV/EBIT
49.79
EV/EBITDA
33.75
EV/Sales
1.59
The EPS has soared by 127% YoY and by 108% from the previous quarter
The stock's price to book (P/B) is 64% less than its 5-year quarterly average of 2.9 and 26% less than its last 4 quarters average of 1.4
The company's equity rose by 45% QoQ but it fell by 8% YoY
The P/S is 92% below the 5-year quarterly average of 24.1 and 49% below the last 4 quarters average of 3.6
Arvinas's revenue has decreased by 15% YoY

Efficiency

How efficient is Arvinas business performance
The company's return on invested capital has surged by 120% YoY and by 105% QoQ
ARVN's return on assets has surged by 119% year-on-year and by 105% since the previous quarter
The ROS has soared by 116% YoY and by 101% from the previous quarter
ARVN's return on equity has surged by 116% year-on-year and by 104% since the previous quarter

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
Arvinas's total liabilities has plunged by 62% YoY and by 57% from the previous quarter
ARVN's current ratio is up by 45% QoQ and by 40% YoY
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% from the previous quarter and by 50% YoY
The company's equity rose by 45% QoQ but it fell by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.